ONCO Key Statistics, Chart & Performance
The current stock price of ONCO is 1.72 USD. In the past month the price decreased by -38.57%. In the past year, price decreased by -96.03%.
ONCO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About ONCO
Company Profile
Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company is headquartered in Cincinnati, Ohio and currently employs 5 full-time employees. The company went IPO on 2022-02-18. The firm owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
Company Info
ONCONETIX INC
201 E. Fifth Street, Suite 1900
Cincinnati OHIO US
Employees: 5
Phone: 15136204101
ONCONETIX INC / ONCO FAQ
What does ONCONETIX INC do?
Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company is headquartered in Cincinnati, Ohio and currently employs 5 full-time employees. The company went IPO on 2022-02-18. The firm owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
What is the stock price of ONCONETIX INC today?
The current stock price of ONCO is 1.72 USD.
Does ONCONETIX INC pay dividends?
ONCO does not pay a dividend.
What is the ChartMill rating of ONCONETIX INC stock?
ONCO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the market capitalization of ONCO stock?
ONCONETIX INC (ONCO) has a market capitalization of 2.68M USD. This makes ONCO a Nano Cap stock.
When does ONCONETIX INC (ONCO) report earnings?
ONCONETIX INC (ONCO) will report earnings on 2026-06-01, after the market close.
ONCO Technical Analysis
ONCO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ONCO. Both the profitability and financial health of ONCO have multiple concerns.
ONCO Financial Highlights
Over the last trailing twelve months ONCO reported a non-GAAP Earnings per Share(EPS) of -350.74. The EPS increased by 95.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -258.38% | ||
| ROE | -1506.13% | ||
| Debt/Equity | 0.05 |